We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Procter & Gamble, Verizon, Thermo Fisher Scientific, Nvidia and Nike
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 29, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Procter & Gamble Company (PG - Free Report) , Verizon Communications Inc. (VZ - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , NVIDIA Corporation (NVDA - Free Report) and NIKE, Inc. (NKE - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for P&G, Verizon and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble, Verizon Communications and Thermo Fisher Scientific. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Procter & Gamble shares have outperformed the Zacks Soap and Cleaning Materials industry in the year to date period (+11.8% vs. +10.3%). The Zacks analyst believes that the company’s efforts to make its cleaning and personal care products available during the current pandemic have helped bolster sales.
Further, rise in shipment volume and better pricing aided sales in the fourth quarter. Top line gained from organic sales growth, driven by rise in organic shipment volume and better pricing. Encouragingly, it issued an upbeat fiscal 2021 view. Further, cost savings aided core currency-neutral gross and operating margin by 250 bps and 190 bps, respectively.
Also, it delivered adjusted free cash flow productivity of 114% in the fiscal fourth quarter. However, currency fluctuations have weighed on the margins and will likely impact fiscal 2021 results. Additionally, stiff competition remains a woe.
Shares of Verizon have lost -1.4% over the past year against the Zacks Wireless National industry’s fall of -2%. The Zacks analyst believes that Verizon is likely to benefit from a disciplined network strategy, including accelerated 5G deployment despite economic uncertainties stemming from the COVID-19 crisis.
Verizon, in association with Amazon Web Services, has added three more 5G mobile edge computing cities — Atlanta, New York City and Washington, DC — bringing the total to five. The company has been building its 5G Ultra Wideband network to enable innovations that will support the changing behavior of customers. Verizon completed the world’s first end-to-end fully virtualized 5G data session in a live network.
It has inked a deal to acquire TracFone — a subsidiary of Mexico’s largest telecommunications company, America Movil. However, Verizon is facing challenges within the media business due to sluggish advertising trends. It operates in a fiercely competitive U.S. wireless market that strains margins. The company is spending heavily on promotion and lucrative discounts to attract customers, which erodes profitability.
Thermo Fisher shares have gained 50.1% over the past six months against the Zacks Medical Instruments industry’s rise of 31%. The Zacks analyst is encouraged by the exceptionally strong year-over-year revenue growth at Life Sciences Solutions segment. Furthermore, pharma and biotech registered growth on the back of robust performances in bioproduction and pharma services businesses.
The COVID-19 sales also boosted the company’s quarterly results. A strong capital structure looks encouraging. Its second quarter results were better-than-expected. Thermo Fisher has outperformed its industry in the past six months.
However, the coronavirus outbreak has massively disrupted the global supply chain. Two of the end markets registered loss in the first quarter, largely due to customer shutdowns in China.
Other noteworthy reports we are featuring today include NVIDIA and NIKE.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Procter & Gamble, Verizon, Thermo Fisher Scientific, Nvidia and Nike
For Immediate Release
Chicago, IL – September 29, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Procter & Gamble Company (PG - Free Report) , Verizon Communications Inc. (VZ - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , NVIDIA Corporation (NVDA - Free Report) and NIKE, Inc. (NKE - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for P&G, Verizon and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble, Verizon Communications and Thermo Fisher Scientific. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Procter & Gamble shares have outperformed the Zacks Soap and Cleaning Materials industry in the year to date period (+11.8% vs. +10.3%). The Zacks analyst believes that the company’s efforts to make its cleaning and personal care products available during the current pandemic have helped bolster sales.
Further, rise in shipment volume and better pricing aided sales in the fourth quarter. Top line gained from organic sales growth, driven by rise in organic shipment volume and better pricing. Encouragingly, it issued an upbeat fiscal 2021 view. Further, cost savings aided core currency-neutral gross and operating margin by 250 bps and 190 bps, respectively.
Also, it delivered adjusted free cash flow productivity of 114% in the fiscal fourth quarter. However, currency fluctuations have weighed on the margins and will likely impact fiscal 2021 results. Additionally, stiff competition remains a woe.
(You can read the full research report on Procter & Gamble here >>>)
Shares of Verizon have lost -1.4% over the past year against the Zacks Wireless National industry’s fall of -2%. The Zacks analyst believes that Verizon is likely to benefit from a disciplined network strategy, including accelerated 5G deployment despite economic uncertainties stemming from the COVID-19 crisis.
Verizon, in association with Amazon Web Services, has added three more 5G mobile edge computing cities — Atlanta, New York City and Washington, DC — bringing the total to five. The company has been building its 5G Ultra Wideband network to enable innovations that will support the changing behavior of customers. Verizon completed the world’s first end-to-end fully virtualized 5G data session in a live network.
It has inked a deal to acquire TracFone — a subsidiary of Mexico’s largest telecommunications company, America Movil. However, Verizon is facing challenges within the media business due to sluggish advertising trends. It operates in a fiercely competitive U.S. wireless market that strains margins. The company is spending heavily on promotion and lucrative discounts to attract customers, which erodes profitability.
(You can read the full research report on Verizon here >>>)
Thermo Fisher shares have gained 50.1% over the past six months against the Zacks Medical Instruments industry’s rise of 31%. The Zacks analyst is encouraged by the exceptionally strong year-over-year revenue growth at Life Sciences Solutions segment. Furthermore, pharma and biotech registered growth on the back of robust performances in bioproduction and pharma services businesses.
The COVID-19 sales also boosted the company’s quarterly results. A strong capital structure looks encouraging. Its second quarter results were better-than-expected. Thermo Fisher has outperformed its industry in the past six months.
However, the coronavirus outbreak has massively disrupted the global supply chain. Two of the end markets registered loss in the first quarter, largely due to customer shutdowns in China.
(You can read the full research report on Thermo Fisher here >>>)
Other noteworthy reports we are featuring today include NVIDIA and NIKE.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.